Direct Therapeutic Ultrasound (DTU) improving surgical safety and precision

“We intend to revolutionize surgical safety and precision,” said Founder and CEO Dr. Stuart Mitchell. “At Novuson, we believe the Ultrastat 3mm MiniLS Vessel Sealer/Divisor will disrupt the surgical market, improving patient safety through DTU precision.”

With the help of StartEngine, we are excited to announce the start of our crowdfunding campaign. Equity crowdfunding allows companies like Novuson to raise capital from the public. Investors will own a partial stake in Novuson and have the opportunity to profit if and when Novuson succeeds. Please find more information about our company, growth plans, financials, investor benefits and more at www.startengine.com/novuson.

ABOUT Novuson:
Novuson, a spin-out of University of Washington The highly regarded Applied Physics Laboratory Industrial and Medical Ultrasound Center is developing its Direct Therapeutic Ultrasound (DTU) technology platform for tissue sealing/splitting, coagulation and hemostatic control in surgical procedures and traumatological. DTU technology should enable clinicians to safely perform surgeries with precision. The founder of the company is Dr. Stuart Mitchell.

Contact
Stuart Mitchelldoctorate
Founder and CEO
(425) 238-6227
[email protected]
https://www.linkedin.com/in/mitchellsb/
https://www.linkedin.com/company/novuson

SOURCE Novuson Surgical

Comments are closed.